Mechanical Ventilation Clinical Trial
Official title:
Post-hoc Analysis of Regional Pulmonary Perfusion and Hemodynamic Parameters Measured by Electrical Impedance Tomography
NCT number | NCT04249414 |
Other study ID # | PV500PERF |
Secondary ID | |
Status | Suspended |
Phase | |
First received | |
Last updated | |
Start date | January 2024 |
Est. completion date | December 2024 |
Verified date | March 2023 |
Source | Drägerwerk AG & Co. KGaA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Define the capability and reliability of the PulmoVista® 500 (PV500) to detect changes in global and regional ventilation and perfusion.
Status | Suspended |
Enrollment | 22 |
Est. completion date | December 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Age 18 - 80 years - Mandatorily ventilated intensive-care patients with impairment in oxygenation (P/F ratio < 300 at PEEP = 5) ventilated at a positive end-expiratory pressure (PEEP) not exceeding 10 mbar and an fraction of inspired oxygen (FiO2) chosen, such that pulse oximetry is sensitive towards arterial oxygen pressure (PaO2) changes. - Expected ventilation time >48h - Existing central venous and arterial access - Chest circumference 70 - 150 cm - Mandatory mechanical ventilation (patients without spontaneous efforts) - Serum levels of sodium and chloride within normal range - Cardiac output monitoring in place (PICCO) Exclusion Criteria: - Contraindication to central venous injection of 5 % sodium chloride (NaCl) (e.g. elevated Na+ and/or Cl- concentration: Na+ should not exceed 150 mmol/l, Chloride should not exceed 115 mmol/l, known hypernatremia, known high serum osmolality) - Contraindications of PulmoVista 500: - Patients with pacemakers, defibrillators or other electrically active implants - Patients with damaged skin or impaired skin contact of the electrodes due to wound dressings - Patients where the attachment of the patient belt could pose a risk to the patient, e.g. patients with spinal lesions or fractures - Patients with uncontrolled body movements - Extremely obese patients (BMI>50) - Patients during pregnancy - Patients with massive lung edema - Use during electricity-based therapies, such as electrosurgery or electrocautery - Use in the presence of strong magnetic fields - Use in conjunction with other bioimpedance measurement devices - Infection or colonization with multi-resistant pathogens that require isolation of the patient (e.g. MRSA) |
Country | Name | City | State |
---|---|---|---|
Germany | University Medical Center Göttingen | Göttingen |
Lead Sponsor | Collaborator |
---|---|
Drägerwerk AG & Co. KGaA | Prof. Dr. med. Imhoff, University of Göttingen |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess regional distribution of pulmonary perfusion | The capability of PulmoVista® 500 for assessing regional distribution of pulmonary perfusion based on pulsatility signals and based on indicator dilution and changes at different points in time during varying states of regional ventilation will be evaluated. | within 24 hours | |
Secondary | Assess hemodynamic parameter cardiac output | The capability of PulmoVista® 500 for assessing cardiac output (relative values compared to reference given in l/min) will be explored. | within 24 hours | |
Secondary | Assess hemodynamic parameter heart rate | The capability of PulmoVista® 500 for assessing heart rate (1/min) will be explored. | within 24 hours | |
Secondary | Assess hemodynamic parameter stroke volume variability | The capability of PulmoVista® 500 for assessing stroke volume variability (relative value in % for 30 seconds compared to reference given in ml) will be explored. | within 24 hours | |
Secondary | Assess oxygenation status | The capability PulmoVista® 500 for assessing the oxygenation status from both the regional distribution of alveolar ventilation and the regional distribution of pulmonary perfusion will be explored. | within 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05921656 -
Construction and Evaluation of Airway Leakage Risk Model of Patients With Endotracheal Tube
|
||
Recruiting |
NCT03941002 -
Continuous Evaluation of Diaphragm Function
|
N/A | |
Withdrawn |
NCT04288076 -
The Brain and Lung Interaction (BALI) Study
|
N/A | |
Completed |
NCT03031860 -
Semi-quantitative Cough Strength Score (SCSS)
|
N/A | |
Completed |
NCT02545621 -
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
|
||
Completed |
NCT02312869 -
Local Assessment of Management of Burn Patients
|
N/A | |
Completed |
NCT01885442 -
TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients
|
N/A | |
Completed |
NCT01204281 -
Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients
|
Phase 4 | |
Terminated |
NCT01059929 -
Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)
|
Phase 4 | |
Completed |
NCT00824239 -
Intermittent Sedation Versus Daily Interruption of Sedation in Mechanically Ventilated Patients
|
Phase 3 | |
Completed |
NCT00529347 -
Mechanical Ventilation Controlled by the Electrical Activity of the Patient's Diaphragm - Effects of Changes in Ventilator Parameters on Breathing Pattern
|
Phase 1 | |
Unknown status |
NCT00260676 -
Protective Ventilatory Strategy in Potential Organ Donors
|
Phase 3 | |
Terminated |
NCT00205517 -
Sedation and Psychopharmacology in Critical Care
|
N/A | |
Completed |
NCT03281785 -
Ultrasound of Diaphragmatic Musculature in Mechanically Ventilated Patients.
|
N/A | |
Recruiting |
NCT04110613 -
RCT: Early Feeding After PEG Placement
|
N/A | |
Completed |
NCT04410783 -
The Emergency Department Sedation Pilot Trial
|
N/A | |
Recruiting |
NCT04821453 -
NAVA vs. CMV Crossover in Severe BPD
|
N/A | |
Completed |
NCT03930147 -
Ventilation With ASV Mode in Children
|
N/A | |
Recruiting |
NCT05029167 -
REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study)
|
N/A | |
Recruiting |
NCT04849039 -
Lung Microbiota and VAP Development (PULMIVAP)
|